Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
Add more filters










Publication year range
1.
J Clin Invest ; 106(2): 309-18, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10903347

ABSTRACT

A potent and selective inhibitor of the osteoclastic V-H(+)-ATPase, (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6, 6-pentamethylpiperidin-4-yl)-2,4-pentadienamide (SB 242784), was evaluated in two animal models of bone resorption. SB 242784 completely prevented retinoid-induced hypercalcemia in thyroparathyroidectomized (TPTX) rats when administered orally at 10 mg/kg. SB 242784 was highly efficacious in the prevention of ovariectomy-induced bone loss in the rat when administered orally for 6 months at 10 mg/kg/d and was partially effective at 5 mg/kg/d. Its activity was demonstrated by measurement of bone mineral density (BMD), biochemical markers of bone resorption, and histomorphometry. SB 242784 was at least as effective in preventing bone loss as an optimal dose of estrogen. There were no adverse effects of compound administration and no effects on kidney function or urinary acidity. Selectivity of the inhibitor was further studied using an in situ cytochemical assay for bafilomycin-sensitive V-H(+)-ATPase using sections of osteoclastoma and numerous other tissues. SB 242784 inhibited the osteoclast enzyme at 1,000-fold lower concentrations than enzymes in any of the other tissues evaluated. SB 242784 demonstrates the utility of selective inhibition of the osteoclast V-H(+)-ATPase as a novel approach to the prevention of bone loss in humans.


Subject(s)
Bone Resorption/drug therapy , Indoles/therapeutic use , Osteoclasts/enzymology , Osteoporosis/drug therapy , Piperidines/therapeutic use , Proton-Translocating ATPases/antagonists & inhibitors , Vacuolar Proton-Translocating ATPases , Vacuoles/enzymology , Acids/analysis , Administration, Oral , Animals , Benzoates/pharmacology , Bone Density , Drug Interactions , Enzyme Inhibitors/therapeutic use , Estradiol/pharmacology , Female , Femur/pathology , Hypercalcemia/drug therapy , Lumbosacral Region , Osteoclasts/drug effects , Ovariectomy , Parathyroidectomy , Rats , Rats, Sprague-Dawley , Retinoids/pharmacology , Spine/pathology , Thyroidectomy , Urine/chemistry , Vacuoles/drug effects
2.
J Pharmacol Exp Ther ; 291(2): 612-7, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10525079

ABSTRACT

The Arg-Gly-Asp (RGD)-binding integrin alpha(V)beta(3) is highly expressed on osteoclasts and has been proposed to mediate cell-matrix adhesion required for osteoclast-mediated bone resorption. Antagonism of this receptor should prevent stable osteoclast adhesion and thereby inhibit bone resorption. We have generated an orally bioavailable, nonpeptide RGD mimetic alpha(v)beta(3) antagonist, SB 265123, which prevents bone loss in vivo when dosed by oral administration. SB 265123 binds alpha(v)beta(3) and the closely related integrin alpha(v)beta(5) with high affinity (K(i) = 3.5 and 1.3 nM, respectively), but binds only weakly to the related RGD-binding integrins alpha(IIb)beta(3) (K(i) >1 microM) and alpha(5)beta(1) (K(i) >1 microM). The compound inhibits alpha(v)beta(3)-mediated cell adhesion with an IC(50) = 60 nM and more importantly, inhibits human osteoclast-mediated bone resorption in vitro with an IC(50) = 48 nM. In vivo, SB 265123 completely blocks bone resorption in a thyroparathyroidectomized rat model of acute bone resorption when dosed at 2.5 mg/kg/h by continuous i.v. infusion. When dosed orally with 3 to 30 mg/kg b.i.d. , in the ovariectomy-induced rat model of osteoporosis, SB 265123 prevents bone resorption in a dose-dependent fashion. This is the first report of an orally active alpha(v)beta(3) antagonist that is effective at inhibiting bone resorption when dosed in a pharmaceutically acceptable fashion. Such a molecule may provide a novel therapeutic agent for the treatment of postmenopausal osteoporosis.


Subject(s)
Acetates/pharmacology , Aminopyridines/pharmacology , Bone Resorption/prevention & control , Cell Adhesion/drug effects , Platelet Aggregation/drug effects , Receptors, Vitronectin/antagonists & inhibitors , Acetates/chemical synthesis , Acetates/pharmacokinetics , Administration, Oral , Aminopyridines/chemical synthesis , Aminopyridines/pharmacokinetics , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Humans , In Vitro Techniques , Infusions, Intravenous , Integrins/metabolism , Osteoporosis/prevention & control , Ovariectomy , Parathyroidectomy , Protein Binding , Rats , Thyroidectomy , Time Factors
3.
J Bone Miner Res ; 13(12): 1852-61, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9844103

ABSTRACT

Bone formation throughout skeletal growth and remodeling always entails deposition of new bone onto a pre-existing mineralized surface. In contrast, the initial deposition of bone in development requires the formation, ex novo, of the first mineralized structure in a nonmineralized tissue. We investigated the cellular events associated with this initial bone formation, with specific reference to the respective role of cartilage and bone cells in bones which form via a cartilage model. The cellular architecture of initial osteogenic sites was investigated by light, confocal, and electron microscopy (EM) in the membranous ossification of fetal calvarial bones (not forming via a cartilage model) and in the membranous ossification of the bony collars of endochondral bones. Bone sialoprotein (BSP), which is expressed during early phases of bone deposition and has been proposed to be involved in the control of both mineral formation and bone cell-matrix interactions, was used as a marker of initial bone formation. We found that at all sites, BSP-producing cells (as identified by intracellular immunoreactivity) are arranged in a characteristic vis-à-vis (face to face) pattern prior to the appearance of the first mineralizing BSP-immunoreactive extracellular matrix. In perichondral osteogenesis, the vis-à-vis pattern comprises osteoblasts differentiating from the perichondrium/periosteum and early hypertrophic chondrocytes located at the lateral aspects of the rudiment. By EM, the first mineral and the first BSP-immunoreactive sites coincide temporally and spatially in the extracellular matrix at the boundary between cartilage and periosteum. We further showed that in an in vitro avian model of chondrocyte differentiation in vitro to osteoblast-like cells, early hypertrophic chondrocytes replated as adherent cells turned on the expression of high levels of BSP in conjunction with the switch to collagen type I synthesis and matrix mineralization. We propose a model for the priming of bone deposition, i.e., the formation of the first bone structure, in which the architectural layout of cells competent to deposit a mineralizing matrix (the vis-à-vis pattern) determines the polarized deposition of bone. For bones forming via a cartilage model, the priming of bone deposition involves and requires cells that differentiate from early hypertrophic chondrocytes.


Subject(s)
Bone Remodeling/physiology , Chondrocytes/physiology , Osteogenesis/physiology , Animals , Blotting, Western , Calcification, Physiologic , Cell Adhesion , Cell Differentiation , Cell Polarity , Cells, Cultured , Chondrocytes/cytology , Female , Integrin-Binding Sialoprotein , Microscopy, Confocal , Microscopy, Electron , Osteoblasts/cytology , Osteoblasts/physiology , Pregnancy , Rats , Rats, Wistar , Sialoglycoproteins/analysis
4.
Endocrinology ; 139(12): 5224-34, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9832463

ABSTRACT

Idoxifene, a novel selective estrogen receptor modulator, was tested for its effects on bone loss, serum cholesterol, and uterine wet weight and histology in the ovariectomized (Ovx) rat. Idoxifene (0.5 mg/kg x day) completely prevented loss of both lumbar and proximal tibial bone mineral density (BMD). In an intervention study, idoxifene (0.5 and 2.5 mg/kg x day) completely prevented further loss of both lumbar and proximal tibial BMD during a 2-month treatment period commencing 1 month after surgery, when significant loss of BMD had occurred in the Ovx control group. Idoxifene reduced total serum cholesterol, which was maximal at 0.5 mg/kg x day. Idoxifene alone displayed minimal uterotrophic activity in Ovx rats and inhibited the agonist activity of estrogen in intact rats. Histologically, myometrial and endometrial atrophy were observed in both idoxifene and vehicle-treated Ovx rats. In this report, we also provide molecular-based evidence to support the observations in vivo of a novel selective estrogen receptor modulator (SERM) mechanism of action in bone and endometrial cells. Idoxifene is an agonist through the estrogen response element (ERE) and exhibits similar postreceptor effects to estrogen in bone-forming osteoblasts. Idoxifene also stimulates osteoclast apoptosis, and these pleiotropic effects ultimately could contribute to the maintenance of bone homeostasis. However, idoxifene differs from estrogen in a tissue-specific manner. In human endometrial cells, where estrogen is a potent agonist through the ERE, idoxifene has negligible agonist activity. Moreover, idoxifene was able to block estrogen induced gene expression in endometrial cells, which is in agreement with the observation in the intact rat study. In the uterus, idoxifene has a pharmacologically favorable profile, lacking agonist and therefore growth-promoting activity. Together with its cholesterol lowering effect and lack of uterotrophic activity, these data suggest that idoxifene may be effective in the prevention of osteoporosis and other postmenopausal diseases without producing unwanted estrogenic effects on the endometrium.


Subject(s)
Anticholesteremic Agents/pharmacology , Cholesterol/blood , Estrogen Antagonists/pharmacology , Osteoporosis/prevention & control , Ovariectomy , Receptors, Estrogen/drug effects , Tamoxifen/analogs & derivatives , Uterus/anatomy & histology , Animals , Biomarkers , Bone Density/drug effects , Bone and Bones/metabolism , Cells, Cultured , Endometrium/cytology , Endometrium/drug effects , Female , Organ Size/drug effects , Rats , Rats, Sprague-Dawley , Tamoxifen/pharmacology , Time Factors , Uterus/drug effects
5.
J Pharmacol Exp Ther ; 279(3): 1453-61, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8968371

ABSTRACT

SB 203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)imidazole], a selective cytokine suppressive binding protein/p38 kinase inhibitor, was evaluated in several models of cytokine inhibition and inflammatory disease. It was demonstrated clearly to be a potent inhibitor of inflammatory cytokine production in vivo in both mice and rats with IC50 values of 15 to 25 mg/kg. SB 203580 possessed therapeutic activity in collagen-induced arthritis in DBA/LACJ mice with a dose of 50 mg/kg resulting in significant inhibition of paw inflammation and serum amyloid protein levels. Antiarthritic activity was also observed in adjuvant-induced arthritis in the Lewis rat when SB 203580 was administered p.o. at 30 and 60 mg/kg. Evidence for disease-modifying activity in this model was indicated by an improvement in bone mineral density and by histological evaluation. Additional evidence for beneficial effects on bone resorption was provided in the fetal rat long bone assay in which SB 203580 inhibited 45Ca release with an IC50 of 0.6 microM. In keeping with the inhibitory effects on lipopolysaccharide-induced tumor necrosis factor-alpha in mice, SB 203580 was found to reduce mortality in a murine model of endotoxin-induced shock. In immune function studies in mice treated with SB 203580 (60 mg/kg/day for 2 weeks), there was some suppression of an antibody response to ovalbumin, whereas cellular immune functions measured ex vivo were unaffected. This novel profile of activity strongly suggests that cytokine inhibitors could provide significant benefit in the therapy of chronic inflammatory disease.


Subject(s)
Arthritis/metabolism , Bone Resorption/metabolism , Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Imidazoles/pharmacology , Mitogen-Activated Protein Kinases , Pyridines/pharmacology , Shock, Septic/metabolism , Animals , Arachidonic Acid/physiology , Arthritis/immunology , Bone Resorption/immunology , Collagen/physiology , Disease Models, Animal , Female , Male , Mice , Mice, Inbred Strains , Rats , Rats, Inbred Lew , Shock, Septic/immunology , Tumor Necrosis Factor-alpha/physiology , p38 Mitogen-Activated Protein Kinases
6.
Arthritis Rheum ; 39(3): 504-14, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8607900

ABSTRACT

OBJECTIVE: To evaluate the effect of SK&F 106615 on joint integrity in rats with adjuvant-induced arthritis (AIA). METHODS: AIA was induced in Lewis rats on day 0, and the animals were treated either prophylactically (days 0-16 or days 0-23) or therapeutically (days 10-23) with SK&F 106615. Efficacy was determined by measurements of paw inflammation, bone mineral density (BMD) using dual x-ray absorptiometry, and magnetic resonance imaging (MRI). Joint integrity was also determined histologically, and serum interleukin-6 (IL-6) levels were measured as a marker of the antiinflammatory effects of the compound. RESULTS: Prophylactic treatment (days 0-16) of AIA rats with SK&F 106615 significantly inhibited paw volume at doses of 545 mg/kg/day given orally on 5 days each week. Extensive evaluation of joint integrity in rats treated with SK&F 106615 20 mg/kg/day orally for 23 days showed inhibition of paw volume, normalization of BMD, and significant improvement in disease by MRI and histologic assessment compared with the AIA controls. Elevated levels of serum IL-6 in AIA rats were reduced dramatically by SK&F 106615. Therapeutic treatment (days 10-23) resulted in similar protective effects measured by paw inflammation, BMD, and MRI. In the therapeutic protocol, serum IL-6 appeared to be a more sensitive marker of antiinflammatory activity than paw edema. CONCLUSION: Symptoms of AIA in rats are significantly reduced by prophylactic and therapeutic treatment with SK&F 106615. Of particular note, this compound appears to exert a protective effect on joint integrity and to have disease-modifying properties.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Arthritis, Experimental/drug therapy , Spiro Compounds/pharmacology , Absorptiometry, Photon , Animals , Arthritis, Experimental/diagnostic imaging , Bone Density/drug effects , Interleukin-6/blood , Joints/pathology , Magnetic Resonance Imaging , Male , Rats , Rats, Inbred Lew
7.
J Bone Miner Res ; 9(11): 1679-86, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7863818

ABSTRACT

We investigated the determinants of bone formation at individual remodeling sites (BMUs) in cancellous bone from 8 osteologically normal, sex hormone-replete women with endometriosis. All were tetracycline double-labeled (2, 12, 2, and 4 day regime) before iliac bone biopsy. At each BMU the mineral apposition rate (MAR) was determined conventionally from the distance between label midpoints (MAR 1) and also from the distance between the mineralization front and the trailing edge of the second label (MAR 2). MAR 1 and 2 were compared with within-BMU measurements of osteoid width (O.Wi) and the activities of osteoblastic alkaline phosphatase (AP) and succinic dehydrogenase (SDH, an enzyme in the Krebs cycle), both quantitated by microdensitometry. A total of 143 BMUs were evaluated, of which 88 were satisfactory for all measurements and 132 were satisfactory for all but SDH. There was a weak correlation (r = 0.34) between MAR 1 and 2 at individual sites, with a mean difference of 0.49 micron/day (mean MAR 0.82 micron/day). The mean MAR of individual subjects tended to be either increasing or decreasing (F = 16.1, p < 0.01). In linear regressions, MAR 2 was statistically dependent on O.Wi, AP, and SDH (73% of the variance accounted for). In contrast, MAR 1 was weakly correlated with O.Wi and only 30% of its variance was accounted for by AP, SDH, and O.Wi. The variance in the MAR 2 data was inversely increased (p < 0.01) compared with MAR 1 as the number of days of bone formation represented.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Alkaline Phosphatase/metabolism , Bone Density/physiology , Bone Remodeling/physiology , Ilium/metabolism , Osteoblasts/enzymology , Adult , Analysis of Variance , Endometriosis/drug therapy , Endometriosis/pathology , Female , Gonadotropin-Releasing Hormone/therapeutic use , Humans , Ilium/physiology , Monte Carlo Method , Succinate Dehydrogenase/metabolism
8.
J Bone Miner Res ; 9(11): 1687-96, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7863819

ABSTRACT

Monoclonal antibodies (MAb) may provide valuable tools for studying osteoblast differentiation. We therefore raised a panel of MAb reactive with cells of this phenotype using 1,25(OH)2D3-treated human trabecular osteoblast-like cells (HOBS) as the immunogen. Immunohistochemical studies on various tissues, including undecalcified cryostat sections of fetal and adult human bone, identified 11 bone cell-reactive MAb. Of these, 2 demonstrated particularly selective reactivities against osteocytes (OB/M) and osteoblasts (OB/L). These reactivities were also seen in developing bone from rat, rabbit, and marmoset. OB/L and OB/M demonstrated limited reactivity against a small number of human tissues from the extensive panel of substrates tested. Both MAb exhibited reactivity against discrete populations of cells in the large and small intestine. In addition, OB/L reacted with cells in the basal epidermis of skin and OB/M with cells in blood vessel walls. Both antibodies demonstrated reactivity against a variety of cultured osteoblast-like cell lines and other cultured cell types. These MAb may therefore provide a valuable means of studying osteoblast ontogeny.


Subject(s)
Antibodies, Monoclonal/metabolism , Osteoblasts/metabolism , Osteocytes/metabolism , Adult , Aged , Aged, 80 and over , Animals , Antibodies, Monoclonal/biosynthesis , Antibodies, Monoclonal/immunology , Calcitriol/pharmacology , Callithrix , Cell Differentiation/immunology , Cell Differentiation/physiology , Cell Line , Cells, Cultured , Female , Femur Head/metabolism , Flow Cytometry , Humans , Hybridomas , Immunohistochemistry , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Mice , Middle Aged , Osteoarthritis/pathology , Osteoblasts/drug effects , Rabbits , Rats , Ribs/embryology , Ribs/metabolism , Species Specificity
9.
J Bone Miner Res ; 9(8): 1221-8, 1994 Aug.
Article in English | MEDLINE | ID: mdl-7526610

ABSTRACT

Rabbit antisera to bovine osteocalcin were produced independently in two laboratories and their specificities established by western blot analysis. By immunohistochemistry each of the five polyclonal antisera produced an intense cytoplasmic staining in human bone-derived cells. Staining intensity was strongly attenuated by preabsorption of the antisera with osteocalcin. No staining was observed using nonimmune rabbit serum. However, the choice of skin cells as negative controls for osteocalcin synthesis yielded an unexpected positive staining pattern similar to that seen with the bone-derived cells over a range of antiserum dilutions. This was not caused by the uptake of exogenous osteocalcin from the culture medium because a similar pattern of staining was observed when medium was supplemented with osteocalcin-depleted fetal calf serum. Treatment with 1,25-dihydroxyvitamin D3 induced osteocalcin mRNA expression and osteocalcin secretion in cultures of bone-derived cells but not in skin fibroblasts. The results demonstrate that these polyclonal antisera also recognize epitopes shared with other proteins synthesized in culture by skin fibroblasts. Furthermore, three mouse monoclonal antibodies to distinct regions of the osteocalcin molecule show differential staining of human bone-derived cells, skin cells, and osteosarcoma cells (MG63). These observations indicate that the shared epitope residues in the central region of osteocalcin and are consistent with the specific synthesis of osteocalcin by bone cells alone. The observed nonspecificity of many osteocalcin antisera may compromise immunocytochemical studies of the osteoblast phenotype in studies in vitro when based solely on reactivity with inadequately characterized osteocalcin antisera.


Subject(s)
Epitopes/analysis , Fibroblasts/chemistry , Osteoblasts/chemistry , Osteocalcin/analysis , Animals , Antibodies, Monoclonal , Antibody Specificity , Cattle , Cells, Cultured , Humans , Immune Sera , Osteoblasts/classification , RNA, Messenger/analysis , Rabbits
10.
J Histochem Cytochem ; 42(5): 677-80, 1994 May.
Article in English | MEDLINE | ID: mdl-7512588

ABSTRACT

We present evidence for a previously unrecognized differential staining effect of Giemsa solution in fluorescence microscopy. The effect consists of selective fluorescent staining of mineralized bone (and elastic fibers) in tissue sections and, like the classical Romanowsky effect, is based on the differential binding of Eosin Y to tissue structures in the presence of Azur II and Methylene Blue. This effect opens the way to new applications of the Giemsa solution in fluorescence microscopy and in confocal fluorescence microscopy.


Subject(s)
Azure Stains , Bone and Bones/anatomy & histology , Calcification, Physiologic , Fluorescent Dyes , Animals , Bone and Bones/embryology , Cartilage/anatomy & histology , Cartilage/embryology , Eosine Yellowish-(YS) , Methylene Blue , Microscopy, Fluorescence , Rats
11.
J Histochem Cytochem ; 42(5): 599-606, 1994 May.
Article in English | MEDLINE | ID: mdl-8157931

ABSTRACT

It has been proposed that highly biosynthetic cells oxidize fatty acids to generate ATP while maintaining high levels of glucose metabolism through the glycolytic and pentose shunt systems to supply biosynthetic intermediates. We investigated the metabolic strategies and substrate for ATP production in the osteoclast. We used in situ quantitative microcytophotometric techniques to determine the maximal activity of the pentose shunt (glucose-6-phosphate dehydrogenase; G6PD), the glycolytic pathway (glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase; G3PD and LDH), fatty acid oxidation (beta-hydroxyacyl dehydrogenase; HOAD), and the Krebs cycle (succinate dehydrogenase; SDH) in human osteoclasts in situ, and related these enzyme activities to the degree of involvement of the cells in resorption. Unlike other highly biosynthetic cells, such as chondrocytes and macrophage polykaryons, osteoclasts associated with bone resorption were deficient in G3PD, LDH, and G6PD activity. However, osteoclasts did demonstrate a capacity for fatty acid oxidation which increased in cells apposed to the bone surface. The lack of significant glycolytic and pentose shunt activity in the osteoclast provides good evidence that resorbing osteoclasts, unlike phagocytosing macrophage polykaryons, have the metabolic characteristics of cells with greatly reduced capabilities of de novo mRNA synthesis but which do maintain high rates of ATP production. The possibility that the loss of glycolytic activity is a prelude to cell death is discussed.


Subject(s)
Adenosine Triphosphate/biosynthesis , Bone Resorption/metabolism , Osteoclasts/metabolism , Alkaline Phosphatase/metabolism , Cytophotometry , Fatty Acids/metabolism , Glucosephosphate Dehydrogenase/metabolism , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Glycolysis , Humans , L-Lactate Dehydrogenase/metabolism , Macrophages/metabolism , Osteoclasts/enzymology , Oxidation-Reduction , Pentose Phosphate Pathway , Succinate Dehydrogenase/metabolism , Tumor Cells, Cultured
13.
Bone ; 14(3): 321-6, 1993.
Article in English | MEDLINE | ID: mdl-8363875

ABSTRACT

Alkaline phosphatase (ALP) activity was used as a novel histomorphometric index of osteoblastic surfaces involved in mineralization. The enzyme cytochemical reaction was done on sections of low temperature processed, glycol methacrylate (GMA) embedded bone biopsies from 39 patients with various types of renal osteodystrophy (age 48 +/- 12 yrs; 19 males, 20 females) who had received tetracycline labelling. Sets of three serial sections were obtained from each tissue block: the 1st section (2 microns thick) was stained with Methylene blue Azure 11 for morphology; the 2nd section (2 microns thick) was used for ALP cytochemistry; the 3rd section was left unstained for UV microscopy. ALP positive osteogenic cells on bone surfaces displayed either of two distinct morphologies: a) typical plump, 'active' osteoblasts, and b) flat, elongated cells otherwise indistinguishable from 'bonelining cells'. These ALP+ flat cells were in contact with sites of active osteoid and mineral deposition and also codistributed with tetracycline labels outside of, and in continuity with, osteoid seams. Flat lining cells which were ALP negative were never associated with labels. Therefore, ALP activity also provided an objective criterion for differentiating two different 'phenotypes' among flat bone lining cells (ALP+ and ALP-), associated or not associated with matrix mineralization, respectively. The following histomorphometric variables were measured: Ob.S/BS, OS/BS, MS/BS and ALP.S/BS. Ob.S/BS, OS/BS and MS/BS were different in different types of ROD. However, OS/BS always exceeded MS/BS which, in turn, always exceeded Ob.S/BS. ALP.S/BS exceeded OS/BS in controls, mixed ROD and hyperparathyroidism, whereas the reverse occurred in osteomalacia and aplastic bone, due to the abundance of ALP lining cells over nonmineralizing surfaces.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Osteoblasts/ultrastructure , Adult , Aged , Alkaline Phosphatase/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/complications , Chronic Kidney Disease-Mineral and Bone Disorder/pathology , Female , Fluorescence , Histocytochemistry , Humans , Hyperparathyroidism/complications , Hyperparathyroidism/pathology , Male , Middle Aged , Osteoblasts/enzymology , Osteomalacia/complications , Osteomalacia/pathology , Tetracycline
14.
Osteoporos Int ; 3 Suppl 1: 199-203, 1993.
Article in English | MEDLINE | ID: mdl-8461559

ABSTRACT

Previous studies have shown that treatment with daily injections of human parathyroid peptide (hPTH) 1-34 increase axial cancellous bone mass partially at the expense of peripheral cortical bone. In the present work the same hPTH 1-34 regime given for 12 months has been combined with oestrogen or nandrolone therapy to control peripheral bone resorption. Spinal and iliac cancellous (but not cortical) bone increased by 40%-50% above initial values while no perceptible changes occurred in radial cortical or cancellous bone. The evidence of radiokinetic and histomorphometric studies performed before and in the last months of treatment suggested that bone remodeling had proceeded through a transient anabolic phase with increased activation, but that activation had become normal after 11-12 months in the cancellous bone of the ilium whereas it continued to be raised elsewhere in the skeleton. It is concluded that in combination with oestrogens, hPTH peptides given daily injections hold great promise for the treatment of patients with osteoporosis who have already lost substantial amounts of spinal cancellous bone.


Subject(s)
Osteoporosis/drug therapy , Parathyroid Hormone/therapeutic use , Peptide Fragments/therapeutic use , Spinal Diseases/drug therapy , Absorptiometry, Photon , Bone Density , Bone and Bones/pathology , Calcium/metabolism , Humans , Kinetics , Osteogenesis , Osteoporosis/metabolism , Osteoporosis/physiopathology , Strontium Radioisotopes , Teriparatide , Tomography, X-Ray Computed
15.
Calcif Tissue Int ; 53 Suppl 1: S108-12, 1993.
Article in English | MEDLINE | ID: mdl-8275363

ABSTRACT

Hip fracture incidence has shown strong upward secular trends in many societies with wide differences in age adjusted incidence between nations. Falls and reduced physical activity have emerged as the strongest risk factors in epidemiological studies, while clinical investigations have pointed to secondary hyperparathyroidism as an important candidate cause of the loss of femoral cortical bone in old age. Until recently there have been few studies performed directly on the region of interest in the proximal femur. Non-invasive methodology using 85Sr has now been developed by our group for measuring bone formation and (with concurrent serial DXA densitometry) resorption in the femoral neck. Bone turnover averaged about 8% annually in controls. A group of younger cases of femoral fracture showed similar indices of total and regional bone formation to a control group; but their resorption was higher. To further investigate this, a femoral neck bone biopsy technique has been developed which can be applied to fracture cases treated by arthroplasty. Preliminary studies have established that the anatomical asymmetry of the neck in cross-section is considerable and imposes restraints on the interpretation of smaller or incomplete femur biopsies. Prospects are quite good that, in the absence of tetracycline pre-labeling, mineralization can be studied by assessment of alkaline phosphatase-positive surfaces in cryostat sections. Moreover, such sections will permit study of other anatomically localized metabolic activities as well as antigen expression and osteocyte viability. Candidate mechanisms for the regional decline in bone quality as well as bone mass in subjects suffering hip fracture can now be investigated more effectively.


Subject(s)
Bone Remodeling , Hip Fractures/physiopathology , Biomarkers , Bone Resorption/metabolism , Hip Fractures/etiology , Hip Fractures/pathology , Humans , Hyperparathyroidism/complications , Osteoporosis/complications , Osteoporosis/pathology , Osteoporosis/physiopathology , Risk Factors
16.
Calcif Tissue Int ; 52(1): 10-5, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8453500

ABSTRACT

The histologic heterogeneity of osteoporosis relative to normal controls has attracted great interest. There has been controversy as to whether patients with high turnover osteoporosis may convert to a normal or low turnover form, and vice versa. We have studied 44 patients over 12 years by dynamic histomorphometry and 85Sr kinetics+calcium balance performed within 60 days in 20 patients (Group 1) and 75-808 days apart in the remainder (Group 2). In the first group, the histologic tissue level bone formation rate (BFR/BV or BFR/BS) was predictive of the 85Sr measurements of bone formation (r = 0.66 P < 0.01). There was no statistically significant correlation in Group 2 and the regression coefficients were significantly different (P = 0.01). Periodic regression was used to determine if seasonal changes were responsible for this loss of correlation; none was found that was of statistical significance. No systematic changes with time in bone formation were found in Group 2 during the period of observation; nor were consistent secular changes detected when the data for both groups were examined according to procedure date. In conclusion, bone formation may change with time in postmenopausal osteoporosis. Evidence that these changes are systematic was not found and this has implications for the design of treatment studies.


Subject(s)
Bone Development , Osteoporosis, Postmenopausal/physiopathology , Osteoporosis/physiopathology , Aged , Bone Resorption , Calcium/metabolism , Female , Fractures, Spontaneous/pathology , Humans , Ilium , Kinetics , Male , Middle Aged , Osteoporosis/pathology , Osteoporosis, Postmenopausal/pathology , Regression Analysis , Spinal Fractures/pathology
17.
Clin Sci (Lond) ; 83(6): 665-75, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1336436

ABSTRACT

1. A new tracer method is described for the non-invasive measurement of bone formation in the proximal femur. The method is based on our previously described whole-body method using 85Sr as the tracer (Reeve, J., Hesp, R. & Wootton, R. Calcif. Tissue Res. 1976; 22, 191-206). It allows correction to be made for long-term exchange processes within the skeleton. 2. The method has been applied in a study of regional and whole-body bone formation in 12 rehabilitated patients who had previously suffered a fracture of the proximal femur. Twelve healthy control subjects were studied, who were selected for their good health and continued physical activity. The aim was to explore the relationship between bone formation and physical activity. 3. Bone formation was similar in the two groups, both regionally and in the whole body. Based on analyses of four cadaver specimens, bone formation in the proximal femur was about one and two-thirds times that in the whole skeleton when related to mass of calcium in the region of interest. 4. Whole-body bone resorption, estimated from five measurements per subject of hydroxyproline excretion in relation to creatinine excretion, was significantly higher in the fracture patients (P < 0.01, Wilcoxon's test). 5. Estimates of current physical activity (and immediate pre-fracture physical activity) were made with a newly devised questionnaire. Historical levels of physical activity (at ages 15-45 years) were determined with Astrom's questionnaire. No bone formation index correlated with any index of physical activity. Urinary hydroxyproline excretion correlated inversely both with current physical activity and historical physical activity (for both regression coefficients P < 0.01). 6. The results are discussed in the light of our current understanding of the control of bone remodelling by the discrete basic multicellular units of bone. The opportunity to study regional bone resorption by the additional use of serial dual X-ray absorptiometry of the same region will in future allow the direct monitoring of the effects of therapeutic interventions which have been designed to prevent contralateral hip fracture.


Subject(s)
Bone Remodeling/physiology , Femoral Neck Fractures/physiopathology , Aged , Bone Density/physiology , Bone Resorption/physiopathology , Bone and Bones/metabolism , Bone and Bones/pathology , Creatinine/urine , Female , Femoral Neck Fractures/pathology , Humans , Hydroxyproline/urine , Middle Aged , Movement , Osteogenesis/physiology , Strontium Radioisotopes
18.
Clin Endocrinol (Oxf) ; 37(3): 282-9, 1992 Sep.
Article in English | MEDLINE | ID: mdl-1424211

ABSTRACT

OBJECTIVE: We wished to determine whether treatment of vertebral osteoporosis with human parathyroid peptide 1-34 (hPTH 1-34), given as a daily injection with supplementary treatment with hormone replacement therapy (HRT), increases cancellous bone area in the ilium by increasing the size of packets of new bone. DESIGN AND MEASUREMENTS: The width of packets of cancellous bone (wall width) was measured at random intercepts and mean values calculated. Cancellous bone area and perimeter were also measured. Indices of trabecular separation and the complementary quantity trabecular number were derived according to Parfitt's method, as well as trabecular width. Patients were used as their own controls and changes in these indices calculated. Correlations were calculated for data obtained from independent measurements. PATIENTS: We studied eleven women with post-menopausal osteoporosis, diagnosed by fractures after exclusion of causes of secondary osteoporosis. RESULTS: One woman did not comply with her HRT therapy. In the others, treatment with hPTH 1-34 + HRT restored the characteristically depressed pre-treatment values of wall width to normal. Trabecular width increased approximately four times more than wall width. Changes in wall width correlated with changes in cancellous bone area; however, bone area increased considerably more than could be accounted for statistically by changes in wall width. A decrease in trabecular separation was found to account for the additional increase in bone area (P = 0.056). CONCLUSION: hPTH 1-34 + oestrogen and progestagen therapy increases the width of packets of new cancellous bone with consequent increases in the width of trabecular plates.


Subject(s)
Bone and Bones/drug effects , Estrogen Replacement Therapy , Norgestrel/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Parathyroid Hormone/therapeutic use , Peptide Fragments/therapeutic use , Aged , Bone Density/drug effects , Bone and Bones/pathology , Female , Humans , Middle Aged , Osteoporosis, Postmenopausal/pathology , Teriparatide
19.
J Bone Miner Res ; 7(8): 905-12, 1992 Aug.
Article in English | MEDLINE | ID: mdl-1442204

ABSTRACT

It is not feasible to use in vivo tetracycline double labeling to study bone formation in biopsies taken during the emergency fixation of fractures. We therefore compared the trabecular localization and extent of osteoblastic alkaline phosphatase (AP) perimeters with tetracycline and osteoid perimeters in iliac crest biopsies from 7 women with postmenopausal osteoporosis and 13 women without metabolic bone disease. Fresh biopsies were chilled to -70 degrees C, and triplicate serial unfixed undecalcified cryostat sections were cut and reacted for AP, stained for osteoid, or mounted unstained. At individual remodeling sites, the mineralizing perimeter (M.Pm) was measured as the extent of a double or single label accompanied by greater than or equal to 1 lamella of osteoid and greater than or equal to 1 lamella of mineralized matrix between the mineralization front and the adjacent label. Osteoid perimeters (O.Pm) and AP perimeters (AP.Pm) were also measured. In each biopsy there was good agreement between the location of AP and bone formation (kappa statistic, range 0.71-1.0). The overall sensitivity and specificity of AP as an indicator of the location of bone formation were 0.963 and 0.902, respectively. At the level of the basic multicellular unit, in those samples in which greater than 3 active BMUs were found, there was (1) significant positive correlation between the M.Pm and both AP.Pm and AP-positive O.Pm (except 1 patient) and (2) no significant difference between the M.Pm and AP-positive O.Pm (17 of 18 patients and 18 of 18 patients at the tissue level).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Alkaline Phosphatase/metabolism , Bone Diseases, Metabolic/enzymology , Calcification, Physiologic , Osteoblasts/enzymology , Osteogenesis , Osteoporosis, Postmenopausal/enzymology , Adult , Aged , Bone Diseases, Metabolic/physiopathology , Bone and Bones/metabolism , Data Interpretation, Statistical , Female , Humans , Ilium , Middle Aged , Osteoblasts/ultrastructure , Osteoporosis, Postmenopausal/physiopathology
20.
Bone Miner ; 17(3): 361-75, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1623330

ABSTRACT

There is considerable current interest in whether activators of bone remodelling, such as IL-1 and other cytokines, are involved in the pathogenesis of osteoporosis. We have therefore studied indices relating to remodelling activation in 50 patients with postmenopausal vertebral osteoporosis and 12 with hip fracture osteoporosis in comparison with 25 age- and sex-matched controls. Because of uncertainty regarding the accuracy of current biochemical markers of bone formation with respect to the estimation of whole body rates of bone formation, a 85Sr-based radioisotopic method was used. This method was previously validated by comparison with data obtained after double in vivo labelling of transiliac biopsies taken nearly simultaneously. Bone resorption was estimated from urinary hydroxyproline data. Controls selected for their continued good health showed a progressive and statistically highly significant decline in indices of bone formation with time after menopause. No such decline was seen in the vertebral fracture patients (P less than 0.005). There were no hip fracture patients within 10 years of menopause so this statistical test could not be applied appropriately to them. The hydroxyproline data were consistent with the suggestion arising from the bone formation data that remodelling declines progressively after menopause in the controls but not in the vertebral fracture patients. The data also suggested that these two fracture groups were in more negative calcium balance than the controls, this being particularly marked in the hip fracture cases. Plasma osteocalcin data correlated moderately well with the kinetic measurements of bone formation. It is concluded that vertebral fracture osteoporosis is associated with prolongation of menopausal levels of bone remodelling which is inappropriate by comparison with healthy controls.


Subject(s)
Bone Remodeling/physiology , Fractures, Bone/physiopathology , Osteoporosis, Postmenopausal/physiopathology , Age Factors , Aged , Alkaline Phosphatase/blood , Bone Resorption/metabolism , Creatinine/metabolism , Female , Humans , Hydroxyproline/metabolism , Kinetics , Middle Aged , Osteocalcin/blood , Spinal Fractures/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...